Drug Dolution for Liver Metastases - Medical / Health Care - Clinical Services
One of the that cancer can be a serious disease is its ability to spread to other parts of the body beyond the location of the primary tumour. When cancer cells spread to distant lymph nodes, tissues or organs, it is called metastatic cancer
-
Most popular related searches
Overview Applications & Industries
LIVER METASTASES ARE CRITICAL
The liver is the second most common organ for metastasis after the lymph nodes. Up to 50-70% of patients with colorectal cancer develop liver metastases, and liver metastases seem to play a significant role in the cause of death of patients who die with breast or colorectal cancer.
The earlier metastases are detected, the better the chances for successful medical intervention, and ultimately patient survival.
DETECTION AND VISUALIZATION ARE CRITICAL FOR THE M...
DETECTION AND VISUALIZATION ARE CRITICAL FOR THE MANAGEMENT OF LIVER METASTASES
Correct and early diagnosis is essential *or the management of patients with liver metastases. Non-invasive imagingpiays anim porta nt role in initial dia gnosis, pre-operative planning, monitorin g of treatment effect, and in surveillance for disease recurrence.
If liver metastases are accurately detected, and deemed eligible for surgical removal, the prognosis can be improved and full recovery is sometimes possible.
MRUS THE RECOMMENDED IMAGING MODALITY
Magnetic Resonance Imaging(MRI) enhanced with a contrast agent is considered the preferred and most sensitive imaging modality for clinical non-invasive assessment of liver metastases and primary liver cancer.
This imaging method uses radio waves and strong magnets to create valuable diagnostic images. Unlike CT and PET-CT. these images are made without exposing the patient to radiation.
CONTRAST AGENTS IMPROVE MRI-SCANS
This is due to the special magnetic properties of the elements in the contrast agent, which aim to increase the sensitivity and specificity of the image compared to an MRI without the use of a contrast agent.
Currently available MRI contrast agents are based on the toxic heavy metal gadolinium.
CONTRAST AGENTS CURRENTLY ON THE MARKET ARE NOT FO...
CONTRAST AGENTS CURRENTLY ON THE MARKET ARE NOT FOR EVERYONE -MANGORAL AIMS TO FILL THIS GAP
Patients with severely impaired kidney function, who are exposed to the gadolinium used in currently available contrast agents, are at risk of the serious and potentially fatal condition Nephrogenic Systemic Fibrosis (NSF).
NSF is a rare, but serious and life-threatening condition that causes extensive waxy thickening and hardening of the skin. It can lead to joint contractures and muscle and fascial fibrosis, which may lead to severe immobility. It can also affect the inner organs. NSF worsens overtime and can cause death, which typically results from multi-system failure due to sclerotic transformation of organ systems.
Regulatory agencies, including the FDA and EMA, have released warnings about the use of GBCAs and clinical guidelines provide restrictions for the use in patients with severe kidney impairment. Therefore, all gadolinium-based contrast agents (GBCAs) have black box warnings in their label for this patient population.
Today, the standard management of patients with severely impaired kidney function is liver MRI without a contrast agent: also called an unenhanced MRI. However, this reduces the ability to detect and visualize, and therefore optimally treat liver metastases. An unenhanced MRI consequently risks reducing patients' chances of survival.
There is. therefore, a need for a safer liver contrast agent for patients with severely impaired kidney function. Mangoral aims to fill this role and be the standard of care for this patient population.
